29.08.2022 13:19:32

Moderna's Omicron-targeting Booster Covid-19 Vaccine Gets Clearance In Switzerland

(RTTNews) - Moderna, Inc. (MRNA) said on Monday that it has received a temporary authorization in Switzerland for its Omicron-targeting bivalent booster vaccine, Spikevax Bivalent Original/Omicron or mRNA-1273.214, to prevent Covid-19 among the people above 18 years.

Spikevax Bivalent Original/Omicron is a bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax), and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

Study results showed that mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273.

Moderna aims to make Spikevax Bivalent Original/Omicron available to the Swiss people in early September.

The drug major has already received approval for mRNA-1273.214 in the UK, and has also completed regulatory submissions for the next-generation vaccine worldwide.

Analysen zu Moderna Incmehr Analysen

19.11.24 Moderna Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
13.09.24 Moderna Underweight JP Morgan Chase & Co.
05.08.24 Moderna Sector Perform RBC Capital Markets
12.01.24 Moderna Outperform RBC Capital Markets
03.11.23 Moderna Buy Goldman Sachs Group Inc.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Moderna Inc 39,29 -0,91% Moderna Inc